Italia markets closed

Dow Jones
39.431,51
-81,33(-0,21%)
Nasdaq
16.388,24
+47,37(+0,29%)
Nikkei 225
38.179,46
-49,65(-0,13%)
EUR/USD
1,0792
+0,0020(+0,18%)
Bitcoin EUR
58.487,91
+1.629,77(+2,87%)
CMC Crypto 200
1.297,40
+37,20(+2,95%)

Neurocrine Biosciences, Inc. (0K6R.L)

LSE - LSE Prezzo differito. Valuta in USD.

Aggiungi a watchlist

136,22

-0,66

(-0,48%)

Alla chiusura: 07:10PM BST

Capitalizzazione	134,057M
Beta (5 anni mensile)	0,28
Rapporto PE (ttm)	1,87
EPS (ttm)	0,73
Prossima data utili	30 lug 2024 - 05 ago 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	N/D

Tutte

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat